Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor (5R)-8-amino-3-fluoro-5,19-dimethyl-20-oxo-5,18,19,20- tetrahydro-7,11-(azeno)pyrido(2',1':2,3)imidazo(4,5-h)(2,5,11) benzoxadiazacyclotetradecine-14-carbonitrile

Structure of the Human Anaplastic Lymphoma Kinase in Complex with the inhibitor (5R)-8-amino-3-fluoro-5,19-dimethyl-20-oxo-5,18,19,20- tetrahydro-7,11-(azeno)pyrido(2',1':2,3)imidazo(4,5-h)(2,5,11) benzoxadiazacyclotetradecine-14-carbonitrile Descriptor: (5R)-8-amino-3-fluoro-5,19-dimethyl-20-oxo-5,18,19,20-tetrahydro-11,7-(azeno)pyrido[2',1':2,3]imidazo[4,5-h][2,5,11]benzoxadiazacyclotetradecine-14-carbonitrile, ALK TYROSINE KINASE RECEPTOR Authors: McTigue, M.A, Deng, Y.L, Liu, W, Brooun, A, Stewart, A.E. Deposit date: 2014-03-12 Release date: 2014-05-28 Last modified: 2023-12-20 Method: X-RAY DIFFRACTION (1.79 Å) Cite: Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant Mutations. J.Med.Chem., 57, 2014

人类间变性淋巴瘤激酶（Anaplastic Lymphoma Kinase, ALK）与抑制剂(5R)-8-氨基-3-氟-5,19-二甲基-20-氧代-5,18,19,20-四氢-7,11-(偶氮桥)吡啶并[2',1':2,3]咪唑并[4,5-h][2,5,11]苯并氧杂二氮杂环十四烷-14-甲腈形成复合物的晶体结构
描述符：(5R)-8-氨基-3-氟-5,19-二甲基-20-氧代-5,18,19,20-四氢-11,7-(偶氮桥)吡啶并[2',1':2,3]咪唑并[4,5-h][2,5,11]苯并氧杂二氮杂环十四烷-14-甲腈，间变性淋巴瘤激酶酪氨酸激酶受体（ALK）
作者：McTigue, M.A.、Deng, Y.L.、Liu, W.、Brooun, A.、Stewart, A.E.
存档日期：2014-03-12
发布日期：2014-05-28
最后修改日期：2023-12-20
实验方法：X射线衍射（分辨率1.79埃）
引用文献：《(10R)-7-氨基-12-氟-2,10,16-三甲基-15-氧代-10,15,16,17-四氢-2H-8,4-(亚甲基桥)吡唑并[4,3-h][2,5,11]苯并氧杂二氮杂环十四烷-3-甲腈（PF-06463922）：一种兼具临床前脑暴露活性与广谱抗ALK耐药突变活性的ALK/ROS1大环类抑制剂》，《药物化学杂志（J. Med. Chem.）》，57卷，2014年